Identification of Gut Microbial Metabolites of a Synthetic Nitric Oxide-Releasing Farnesylthiosalicylic Acid Derivative, an Antitumor Agent

REFERENCES

• Aura , A. M. 2008 . Microbial metabolism of dietary phenolic compounds in the colon . Phytochem. Rev. 7 : 407 – 429 .
   Google Scholar
• Bos , J. L. 1988 . The ras gene family and human carcinogenesis . Mutat. Res. 195 : 255 – 271 .
   PubMed Web of Science ®Google Scholar
• Calvisi , D. F. , S. Ladu , A. Gorden , M. Farina , E. A. Conner , J. S. Lee , V. M. Factor , and S. S. Thorgeirsson . 2006 . Ubiquitous activation of Ras and Jak/Stat pathways in HCC . Gastroenterology 130 : 1117 – 1128 .
   PubMed Web of Science ®Google Scholar
• Fukuto , J. M. , and D. A. Wink . 1999 . Nitric oxide (NO): Formation and biological roles in mammalian systems . Met. Ions Biol. Syst. 36 : 547 – 595 .
   PubMedGoogle Scholar
• Gasco , A. , R. Fruttero , G. Sorba , A. Distilo , and R. Calvino . 2004 . NO donors: Focus on furoxan derivatives . Pure Appl. Chem. 76 : 973 – 981 .
   Web of Science ®Google Scholar
• Hwang , K. J. , L. Jo , Y. A. Shin , S. Yoo , and J. H. Lee . 1995 . Furoxans as potential nitric oxide generator: Mechanistic speculation on the electron impacted fragmentation . Tetrahedron Lett. 36 : 3337 – 3340 .
   Web of Science ®Google Scholar
• Ling , Y. , X. L. Ye , H. Ji , Y. H. Zhang , Y. S. Lai , S. X. Peng , and J. D. Tian . 2010. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. Bioorg. Med. Chem. 18: 3448–3456.
   PubMed Web of Science ®Google Scholar
• Ling , Y. , X. L. Ye , Z. Z. Zhang , Y. H. Zhang , Y. S. Lai , H. Ji , S. X. Peng , and J. D. Tian . 2011 . Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: Synthesis and evaluation of antihepatocellular carcinoma activity . J. Med. Chem. 54 : 3251 – 3259 .
   PubMed Web of Science ®Google Scholar
• Llovet , J. M. , and J. Bruix . 2008 . Novel advancements in the management of hepatocellular carcinoma in 2008 . J. Hepatol. 48 ( Suppl . 1 ): S20 – 37 .
   PubMedGoogle Scholar
• Mocellin , S. 2009 . Nitric oxide: Cancer target or anticancer agent? Curr. Cancer Drug Targets 9 : 214 – 236 .
   PubMed Web of Science ®Google Scholar
• Ogata , N. , T. Kamimura , and H. Asakura . 1991 . Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma . Hepatology 13 : 31 – 37 .
   PubMed Web of Science ®Google Scholar
• Rai , G. , A. A. Sayed , W. A. Lea , H. F. Luecke , H. Chakrapani , S. Prast-Nielsen , et al. . 2009 . Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis . J. Med. Chem. 52 : 6474 – 6483 .
   PubMed Web of Science ®Google Scholar
• Richards , C. A. , S. A. Short , S. S. Thorgeirsson , and B. E. Huber . 1990 . Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: Additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis . Cancer Res. 50 : 1521 – 1527 .
   PubMed Web of Science ®Google Scholar
• Rotblat , B. , H. Niv , S. André , H. Kaltner , H. J. Gabius , and Y. Kloog . 2004 . Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP . Cancer Res. 64 : 3112 – 3118 .
   PubMed Web of Science ®Google Scholar
• Tsimberidou , A. M. , M. A. Rudek , D. Hong , C. S. Ng , J. Blair , H. Goldsweig , and R. Kurzrock . 2009 . Phase 1 first-in-human clinical study of S-trans, transfarnesylthiosalicylic acid (salirasib) in patients with solid tumors . Cancer Chemother. Pharmacol. 65 : 235 – 241 .
   Web of Science ®Google Scholar
• Yang , L. F. , Y. Ling , Z. Z. Zhang , Q. Zhao , J. X. Tang , H. Ji , and Y. H. Zhang . 2011 . ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways . Biochem. Bioph. Res. CO. 409 : 752 – 757 .
   PubMed Web of Science ®Google Scholar
• Yoshida , T. , T. Hisamoto , J. Akiba , H. Koga , K. Nakamura , Y. Tokunaga , et al. . 2006 . Spreads, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors . Oncogene 25 : 6056 – 6066 .
   PubMed Web of Science ®Google Scholar